An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
Free online course: learn how to be an effective Parkinson’s campaigner
More than 500 people have completed the programme so far
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.